ArriVent BioPharma Initiated at Buy by HC Wainwright & Co.

ArriVent BioPharma Initiated at Buy by HC Wainwright & Co.

Dow JonesApr 30 18:22

HC Wainwright & Co. Initiates Coverage On ArriVent BioPharma With Buy Rating, Announces Price Target of $25

HC Wainwright & Co. analyst Robert Burns initiates coverage on ArriVent BioPharma with a Buy rating and announces Price Target of $25.

Analyst UpgradesApr 30 18:12

Press Release: ArriVent Appoints Kristine Peterson to Its Board of Directors

ArriVent Appoints Kristine Peterson to its Board of Directors NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the g

Dow JonesApr 23 04:05

Jefferies Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)

TipRanksApr 11 19:55

Buy Rating on ArriVent BioPharma Highlighting Furmonertinib's Potential in NSCLC Treatment Landscape

TipRanksApr 1 17:55

ArriVent BioPharma FY23 EPS $(32.38) Vs $(28.90) YoY

Fiscal Year 2023 Financial ResultsResearch and development expenses were $64.9 million and $30.4 million for the years ended December 31, 2023 and 2022, respectively. The increase in expense was prima

BenzingaMar 29 04:38